Antengene Reports the First Patient Dosing in the P-I Trial (ERASER) of ATG-017 + Nivolumab for the Treatment of Advanced Solid Tumors
Shots:
- The first patient has been dosed in the P-I trial (ERASER) evaluating the safety/tolerability, PK, and preliminary efficacy of ATG-017 + nivolumab in patients with advanced solid tumors
- The preclinical results of ATG-017 showed highly specific selectivity and promising activity, as well as synergistic effects in combination with ICIs. Additionally, the monotx. portion of the (ERASER) study is currently ongoing in Australia while the combination portion in both the US and Australia
- ATG-017, an oral, potent, and selective small molecule extracellular signal-regulated kinases 1 and 2 (ERK1/2) inhibitor. The company continues to advance the clinical program of ATG-017
Ref: PR Newswire | Image: Antengene
Related News:- Antengene Receives the US FDA’s IND Clearance of ATG-017 to Initiate P-I (ERASER) Trial for Advanced Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
